Evaluation of lncRNA CCAT2 expression in tumor tissue and marginal tumor colorectal cancer patients

Abstract

Cancer is a genetic disease of somatic cells due to abnormal cell division or loss of normal cell death (apoptosis). Cancer is now the second leading cause of death after cardiovascular disease. Bowel cancer is the second most common cancer in most developed countries and is less prevalent in most developing countries. About 15 to 20 percent of colorectal cancer (CRC) cases are inherited. Projects such as transcriptome have shown that most human genomes are transcribed into non-coding RNAs, which have different types, most of which play a regulatory role. The largest group of non-coding RNAs is the long non-coding RNA (lncRNA), which plays different roles in regulating the expression of different genes and cell activities, and also plays an important role in the growth and development of human cancers, including They have colorectal cancer (CRC). The CCAT-2 gene has been studied as an antisense lncRNA in prostate and lung cancers and has been shown to be a useful diagnostic and prognostic marker for these cancers

Materials and Methods: In this study, 50 samples of tumor tissue and 50 samples of tumor margins of cancer patients, including 32 men and 18 women, were examined. Isolate RNA from the tissues by the extraction kit (Trizol), perform cDNA synthesis from the extracted RNA, then perform Real Time PCR for the CCAT-2 gene as the target gene and GAPDH as the internal control gene, and Finally, we have performed statistical analysis by software Results According to the results of the study, the expression of CCAT-2 lncRNA in colorectal cancer tumor tissue increased significantly compared to healthy marginal tissue. Therefore, with further investigation, the CCAT-2 gene can be used as one of the diagnostic or predictive biomarkers for colorectal cancer and can most likely be used to differentiate tumor tissue and tumor margin during surgical procedures. , But further studies are needed to prove this claim.